Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

zanolimumab

Known as: Anti-CD4 Monoclonal Antibody HuMax, HuMax-CD4 
A human IgG1k monoclonal antibody against the CD4 receptor on T-lymphocytes, with potential antineoplastic and immunosuppressing activities… Expand
National Institutes of Health

Related topics

Related topics

2 relations

Broader (1)

Monoclonal Antibodies
antigen binding

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Phase I trial of HuMax-IL8 (BMS-986253), an anti-IL-8 monoclonal antibody, in patients with metastatic or unresectable solid tumors
BackgroundHuMax-IL8 (now known as BMS-986253) is a novel, fully human monoclonal antibody that inhibits interleukin-8 (IL-8), a… Expand
2017
2017
Neutralization of IL-8 decreases tumor PMN-MDSCs and reduces mesenchymalization of claudin-low triple-negative breast cancer.
The complex signaling networks of the tumor microenvironment that facilitate tumor growth and progression toward metastatic… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Review
2016
Review
2016
Cutaneous lymphoma: Kids are not just little people.
Cutaneous T-cell lymphomas (CTCLs) are non-Hodgkin lymphomas that predominantly affect older patients. Onset of cutaneous… Expand
  • figure 3
  • table 1
  • table 3
  • table 4
  • table 5
Highly Cited
2010
Highly Cited
2010
Phase II trial of zanolimumab (HuMax‐CD4) in relapsed or refractory non‐cutaneous peripheral T cell lymphoma
The efficacy and safety of zanolimumab (HuMax‐CD4) in patients with relapsed or refractory peripheral T Cell lymphoma (PTCL) was… Expand
Review
2008
Review
2008
Novel human antibody therapeutics: The age of the Umabs
Monoclonal antibodies represent a major and increasingly important category of biotechnology products for the treatment of human… Expand
Highly Cited
2007
Highly Cited
2007
Clinical efficacy of zanolimumab (HuMax-CD4): two phase 2 studies in refractory cutaneous T-cell lymphoma.
The efficacy and safety of zanolimumab in patients with refractory cutaneous T-cell lymphoma (CTCL) have been assessed in two… Expand
  • table 1
  • table 2
  • table 3
  • table 4
  • figure 2
2007
2007
Zanolimumab (HuMax-CD4™), a Fully Human Monoclonal Antibody: Efficacy and Safety in Patients with Relapsed or Treatment-Refractory Non-Cutaneous CD4+ T-Cell Lymphoma.
Combination chemotherapy has been the basis of treatment for peripheral T-cell lymphoma (PTCL) for many years, but relapses are… Expand
Highly Cited
2005
Highly Cited
2005
Targeting interleukin-15 in patients with rheumatoid arthritis: a proof-of-concept study.
OBJECTIVE Interleukin-15 (IL-15) is a proinflammatory, innate response cytokine that mediates pleiotropic effector function in… Expand
2005
2005
Treatment of a patient with a nodal peripheral T-cell lymphoma (Angioimmunoblastic T-cell lymphoma) with a human monoclonal antibody against the CD4 antigen (HuMax-CD4)
A patient with a CD4+ refractory peripheral T-cell lymphoma (PTL), subtype angioimmunoblastic T-cell lymphoma (AILD), was treated… Expand
  • table 1
Highly Cited
2003
Highly Cited
2003
HuMax-CD4: a fully human monoclonal anti-CD4 antibody for the treatment of psoriasis vulgaris.
BACKGROUND Psoriasis is characterized by infiltration with mononuclear cells. Especially activated memory CD4+ T cells are… Expand
  • table 1
  • table 2
  • figure 1
  • figure 2
  • figure 3
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE